Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
145 studies found for:    PTEN
Show Display Options
Rank Status Study
1 Recruiting Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations
Conditions: PTEN;   ASD;   Autism;   Macrocephaly;   PTEN Hamartoma Tumor Syndrome
2 Completed A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency
Condition: Cancer
Intervention: Drug: GSK2636771
3 Withdrawn PTEN and IGFBP-3 Correlation in Ovarian Carcinoma Invasion
Condition: Ovarian Cancer
Intervention: Procedure: immunohistochemical, methylation, gene transfection
4 Recruiting The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia
Condition: Chronic Myelomonocytic Leukemia
5 Recruiting The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients With Biochemical Failure Status Post Salvage or Radical Radiation Therapy
Condition: Prostate Cancer
6 Recruiting Relationship Between PTEN and Glycemic Variability and Outcome in Critically Ill Patients
Conditions: Critical Illness;   Hyperglycemia
7 Completed
Has Results
Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes
Conditions: Cowden's Disease;   Hamartoma Syndrome, Multiple
Interventions: Radiation: fludeoxyglucose F 18;   Drug: sirolimus;   Other: Clinical Videography
8 Completed Studies of the Tumour Suppressor Gene PTEN - Endometrial Cancer
Condition: Endometrial Neoplasms
Interventions: Behavioral: questionnaire;   Procedure: Blood sample-DNA testing / Tumour-genetic markers
9 Active, not recruiting Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
Conditions: Advanced Cancers;   Solid Tumors
Interventions: Drug: Pazopanib;   Drug: Everolimus
10 Active, not recruiting Triple Negative Breast Cancer: Study of Molecular and Genetic Factors
Condition: Breast Cancer
Intervention: Genetic: BRCA1 BRCA2 PTEN PALB2 mutation
11 Recruiting Phase 1 Study of ARQ 751 in Solid Tumors With AKT1, 2, 3 Genetic Alterations, Activating PI3K Mutations or PTEN-null
Conditions: Cancer;   Solid Tumors
Intervention: Drug: ARQ 751
12 Unknown  Can Dormant Perimenopausal Ovarian Follicles Become FSH Responsive?
Conditions: Low Ovarian Reserve;   Poor Responders to Gonadotropihins Treatment
Intervention: Other: Removal of half an ovary
13 Recruiting Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
Conditions: Advanced Solid Malignancy;   Safety and Tolerability;   Pharmacokinetics;   Pharmacodynamics;   Tumour Response;   Advanced or Metastatic Breast Cancer;   Ovarian Cancer;   Cervical Cancer;   Endometrial Cancer;   PIK3CA;   AKT1;   PTEN;   ER Positive;   HER2 Positive
Intervention: Drug: AZD5363
14 Recruiting Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis
Condition: Prostate Cancer
15 Recruiting Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss
Condition: Carcinoma, Squamous Cell of Head and Neck
Interventions: Drug: Copanlisib;   Drug: Cetuximab
16 Recruiting AZD8186 First Time In Patient Ascending Dose Study
Conditions: Advanced Castrate-resistant Prostate Cancer (CRPC);;   Squamous Non-Small Cell Lung Cancer (sqNSCLC);;   Triple Negative Breast Cancer (TNBC)
Interventions: Drug: AZD8186 monotherapy;   Drug: Part B: AZD8186 monotherapy;   Drug: Part C: Abiraterone acetate in combination with AZD8186;   Drug: Part D1: AZD2014 combination with AZD8186;   Drug: Part D2 AZD2014 combination with AZD8186
17 Completed
Has Results
Genetics, Brain Structure and Thinking Skills in Autism
Condition: Autism Spectrum Disorders
18 Active, not recruiting Studying Tissue Samples From Women With Breast Cancer Who Were Treated on Clinical Trial NCCTG-N9831
Condition: Breast Cancer
Intervention: Other: diagnostic laboratory biomarker analysis
19 Active, not recruiting Phase II Study of BMN 673
Condition: Advanced Cancers
Interventions: Drug: Talazoparib Tosylate;   Behavioral: Phone Call
20 Recruiting Online Study of Individuals With Genetic Changes and Features of Autism: Simons Variation in Individuals Project (Simons VIP)
Conditions: 16p11.2 Deletions;   16p11.2 Duplications;   1q21.1 Deletions;   1q21.1 Duplications;   ADNP (ADNP1, KIAA0784);   ANKRD1 (ANCO1, T13, LZ16);   ARID1B (BAF250B);   ASXL3 (KIAA1713);   BAF105;   BAF180 (PBRM1, PB1);   BAF190 (SMARCA4/SMARCA2);   BAF35 (BCL7B);   BAF35b (ACTL6B);   BCL11A (CTIP1, EVI9, KIAA1809, FLJ10173);   CHD2;   CHD8 (KIAA1564, DUPLIN);   CTNNB1 (CTNNB);   CUL3 (Cullin 3, PHA2E, KIAA0617);   DST (BPAG1, BP240);   DYRK1A;   FOXP1 (QRF1);   GRIN2B (NMDAR2B, NR2B);   KDM6B (JMJD3, KIAA0346);   KMT2E (MLL5);   MBD5 (KIAA1461);   MED13L (THRAP2, PROSIT240, TRAP240L, KIAA1025);   PTEN (PTEN1, MMAC1);   REST (NRSF);   SCN2A;   SMARCC1 (BAF155);   SMARCC2 (BAF170);   SYNGAP1;   Additional Genetic Changes Associated With Autism May be Added as Identified

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years